Accueil   Diary - News   All news Theranexus announces preliminary results of phase II trial of THN102

Theranexus announces preliminary results of phase II trial of THN102

 

Lyon, 27 February 2019 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announces the preliminary results of its Phase II trial in narcolepsy patients.

 

Read the press release